Cardiac Safety of Kinase Inhibitors – Improving Understanding and Prediction of Liabilities in Drug Discovery Using Human Stem Cell-Derived Models

Many small molecule kinase inhibitors (SMKIs) used to fight cancer have been associated with cardiotoxicity in the clinic. Therefore, preventing their failure in clinical development is a priority for preclinical discovery. Our study focused on the integration and concurrent measurement of ATP, apop...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziegler, Ricarda, Häusermann, Fabian, Kirchner, Stephan, Polonchuk, Liudmila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242589/
https://www.ncbi.nlm.nih.gov/pubmed/34222360
http://dx.doi.org/10.3389/fcvm.2021.639824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242589/
https://www.ncbi.nlm.nih.gov/pubmed/34222360
http://dx.doi.org/10.3389/fcvm.2021.639824

Ejemplares similares